Answers are grounded in this paper and cite their sources.
Comparative trial evaluates reparative effects of preconditioned hBM-MSCs post-testicular injury, suggesting distinct recovery patterns.
Non-obstructive azoospermia (NOA) is a severe male-infertility phenotype characterized by intrinsic testicular failure and impaired spermatogenesis. This study compared retinoic acid (RA)- and transforming growth factor-beta 1 (TGF-β1)-preconditioned human bone marrow-derived mesenchymal stem cells (hBM-MSCs) in a busulfan-induced mouse model of testicular injury. hBM-MSCs were characterized by plastic adherence, spindle-shaped morphology, immunophenotyping, and adipogenic/osteogenic differentiation, then preconditioned with RA (2, 5, or 10 µM) or TGF-β1 (5, 10, or 20 ng/mL) for 21 days. Busulfan-treated BALB/c mice were assigned to eight groups (n = 5/group), and preconditioned cells were transplanted four weeks after injury. Histology, modified Johnsen score, spermatogenic indices, seminiferous morphometry, testicular cell counts, epididymal sperm parameters, human-specific Alu-qPCR, and C-Kit, DAZL, OCT4, Tex18, Piwil2, and Mvh transcript expression were evaluated eight weeks after transplantation. Busulfan induced tubular atrophy, germ-cell depletion, impaired sperm-related endpoints, and downregulation of spermatogenesis-associated transcripts. Both preconditioned hBM-MSC products partially attenuated these abnormalities compared with busulfan-only injury. RA-preconditioned hBM-MSCs, particularly at 10 µM, showed the strongest pro-spermatogenic profile, whereas TGF-β1-preconditioned hBM-MSCs showed a comparatively niche-oriented epithelial and luminal recovery pattern. Human Alu-qPCR indicated donor-derived DNA persistence within testes but not viable donor-cell integration or donor-derived spermatogenesis. Because a naïve, non-preconditioned hBM-MSC group was not included, whether unprimed hBM-MSCs would produce similar, lesser, or different effects remains unknown. These findings define distinct reparative profiles, not validated molecular pathways or proven fertility restoration.
No takes yet. Share an insight, caveat, or question.
Omrani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: